InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Huntsman Ronald Kirk, Chief Executive Officer. Insider active across 1 companies, notably Vivos Therapeutics, Inc.. Aggregated, 7 reports have been recorded. Total volume traded: €113k. The latest transaction was filed on 31 May 2022 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
€15,1298,000 shares@ €1.89120.17% mcap13.4% of flow
Common Stock
SEC:0001493152-22-015773:0·
Ideal exit: 25 Feb 2023 (T+270)
€18,3835,000 shares@ €3.676637.7% of flow
Common Stock
SEC:0001493152-21-023354·
Ideal exit: 18 Jun 2022 (T+270)
€18,3835,000 shares@ €3.67660.21% mcap16.3% of flow
Common Stock
SEC:0001493152-21-023354:0·
Ideal exit: 18 Jun 2022 (T+270)
€12,8105,000 shares@ €2.56226.3% of flow
Common Stock
SEC:0001493152-21-020536·
Ideal exit: 14 May 2022 (T+270)
€12,8105,000 shares@ €2.5620.15% mcap11.4% of flow
Common Stock
SEC:0001493152-21-020536:0·
Ideal exit: 14 May 2022 (T+270)
€17,5694,000 shares@ €4.392236.0% of flow
Common Stock
SEC:0001493152-21-012901·
Ideal exit: 19 Feb 2022 (T+270)
€17,5694,000 shares@ €4.39220.20% mcap15.6% of flow
Common Stock
SEC:0001493152-21-012901:0·
Ideal exit: 19 Feb 2022 (T+270)
7 of 7 declarations
About Huntsman Ronald Kirk
Ronald Kirk Huntsman is the Chief Executive Officer of Vivos Therapeutics, Inc. In this role, he is responsible for the strategic and operational leadership of the company. Ronald Huntsman plays a key role in developing innovative therapeutic solutions and optimizing the company's performance. His expertise in management and healthcare is essential for the success of Vivos Therapeutics.
